NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) issued its earnings results on Friday, November, 1st. The company reported ($2.04) EPS for the quarter, missing the consensus estimate of ($1.57) by $0.47. View Biohaven Pharmaceutical's Earnings History.

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

13 brokers have issued 1 year target prices for Biohaven Pharmaceutical's stock. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $70.17 in the next twelve months. This suggests a possible upside of 54.8% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

News articles about BHVN stock have trended extremely negative on Saturday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biohaven Pharmaceutical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Biohaven Pharmaceutical.

Some companies that are related to Biohaven Pharmaceutical include Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN) and United Therapeutics (UTHR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Netflix (NFLX), Baidu (BIDU) and Roku (ROKU).

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Capital International Investors (5.59%), Oracle Investment Management Inc. (3.68%), State Street Corp (3.66%), Capital World Investors (3.15%), Capital International Inc. CA (2.18%) and Eagle Asset Management Inc. (1.43%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

BHVN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Marshall Wace LLP, Eagle Asset Management Inc., Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., State Street Corp, UBS Group AG and Schonfeld Strategic Advisors LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, John Tilton, Kimberly Gentile, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

BHVN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Point72 Asset Management L.P., Pictet Asset Management Ltd., Bluefin Trading LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rhenman & Partners Asset Management AB. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $45.34.

Biohaven Pharmaceutical has a market capitalization of $2.37 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($6.15) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.